Spark Therapeutics, which is developing gene therapy treatments for orphan retinal dystrophies, raised $161 million in an upsized IPO by offering 7 million shares at $23, above the upwardly revised range of $19 to $21. Spark Therapeutics plans to list on the NASDAQ under the symbol ONCE. Spark Therapeutics initially filed confidentially on 9/24/2014. J.P. Morgan and Credit Suisse acted as lead managers on the deal.
